Julphar set to bring new combination cholesterol medicine to UAE

New drugs to be made available locally for first time

  

License and technology transfer agreement completed with Dutch company PharmaMatch BV

High cholesterol one of major factors in rise of cardiovascular diseases

Cardiovascular disease UAE’s biggest killer

Ras Al Khaimah (UAE) -Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, has completed a deal with leading Dutch company, PharmaMatch BV, to launch a novel combination for the treatment of hypercholesterolemia, which is currently unavailable in the UAE market.

The license and technology transfer agreement was signed earlier this month on the sidelines of CPhI Worldwide, the largest pharmaceutical trade fair in the world. Under the terms of the agreement, Julphar will manufacture the combination, which is used to target hypercholesterolemia, a condition characterized by very high levels of cholesterol in the blood.

Commenting on the announcement Jerome Carle, General Manager of Julphar, said, "Bringing new medicines to the local market is something we are very proud to be able to do. We strongly believe in the efficacy and value of these medications. They will have a real impact on the lives of the many people who suffer with high cholesterol".

“We are delighted to be partnering with PharmaMatch BV, a company with a strong reputation and track record in the European market and further afield. Our goal at Julphar from the very beginning of our journey has always been to deliver affordable, quality healthcare solutions. Our relationship with PharmaMatch will enable us to continue to make a difference and I can see our relationship continuing to grow and develop into something very positive.”

High blood cholesterol is a condition that causes the levels of certain bad fats, or lipids, to be too high in the blood. High blood cholesterol is one of the major risk factors for cardiovascular diseases (heart diseases), the leading cause of death in the UAE, which accounts for over two-thirds of all deaths in the country.

Cédric Trouillot, Sales Manager at PharmaMatch, said: “PharmaMatch sees its collaboration with Julphar as a very important step towards expanding its contribution in the MENA region.”

CPhI Worldwide took place in Madrid earlier this month and featured 45,000 visitors and more than 2,500 exhibitors covering the end-to-end supply chain from ingredients, APIs, excipients, contract services, packaging, and machinery. It followed the regional debut of CPhI Middle East in September, where Julphar witnessed particularly strong footfall.

-Ends-

About Julphar

Julphar is one of the largest pharmaceutical manufacturers in the Middle East and Africa and for almost four decades, the company has been delivering high quality, innovative and affordable healthcare solutions to families across the globe. Established under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi in 1980, Julphar employs more than 5,000 people and distributes pharmaceutical products to more than 50 countries on five continents.

Julphar’s business is centered on three core business units – Julphar Diabetes Solutions, General Medicines and its consumer division, Julphar Life – which target major therapeutic segments including Gastrology, Pain Management, Wound Care, Antibiotics and Cardio-metabolism. Julphar has 16 internationally accredited facilities in Africa, Middle East and Asia that produce more than a million boxes of medicines a day. In 2012, Julphar became one of the largest producers of insulin in the world.

For more information, visit http://www.julphar.net 

About PharmaMatch B.V.

PharmaMatch licenses pharmaceutical dossiers of their own products and those of partners in the global market. They focus on generic and niche products, create added value for existing pharmaceutical products and develop their own dossiers. PharmaMatch is a respected partner in the pharmaceutical industry and holds a GMP and GDP license.

For more information, visit http://www.pharmamatch.nl 

For media enquiries, please contact:
Chris Goward
Corporate Communications
Julphar
T: +971 7 246 1461
M: +971 58 263 3997
E: chris.goward@julphar.net

© Press Release 2018

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.


More From Press Releases